PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22391067-8 2012 RESULTS: In TGF-beta-1-induced NPDFs, simvastatin significantly inhibited the expressions of alpha-SMA and collagen type IV mRNA and reduced alpha-SMA and collagen protein levels. Simvastatin 38-49 transforming growth factor beta 1 Homo sapiens 12-22 23817018-0 2013 Simvastatin attenuates TGF-beta1-induced epithelial-mesenchymal transition in human alveolar epithelial cells. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 23-32 23817018-4 2013 However, whether Sim can attenuate TGF-beta1-induced EMT in A549 cells and its underlying mechanisms remains unknown. Simvastatin 17-20 transforming growth factor beta 1 Homo sapiens 35-44 23817018-10 2013 RESULTS: Sim significantly attenuated the TGF-beta1-induced decrease in E-Cad levels and elevated the levels of alpha-SMA, Vi and FN via the suppression of Smad2 and Smad3 phosphorylation. Simvastatin 9-12 transforming growth factor beta 1 Homo sapiens 42-51 22331026-7 2012 Simvastatin significantly increased the number of Tregs and the expression of Treg marker Foxp3 (Forkhead/winged helix transcription factor), transforming growth factor (TGF)-beta and interleukin (IL)-10 in atherosclerotic plaques. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 142-179 22127053-7 2012 Furthermore, SPC induced secretion of TGF-beta1 and pretreatment with either Y27632 or simvastatin inhibited the SPC-induced TGF-beta1 secretion. Simvastatin 87-98 transforming growth factor beta 1 Homo sapiens 125-134 22127053-8 2012 These results suggest that simvastatin inhibits SPC-induced differentiation of hASCs into smooth muscle cells by attenuating the RhoA/Rho kinase-dependent activation of autocrine TGF-beta1/Smad2 signaling pathway. Simvastatin 27-38 transforming growth factor beta 1 Homo sapiens 179-188 22391067-4 2012 METHODS: NPDFs were pretreated with simvastatin with or without mevalonate or Y-27643 for 2 hours before induction by TGF-beta-1. Simvastatin 36-47 transforming growth factor beta 1 Homo sapiens 118-128 22391067-11 2012 The TGF-beta-1-induced expression of pSmad 2/3 protein was notably decreased by pretreatment with simvastatin. Simvastatin 98-109 transforming growth factor beta 1 Homo sapiens 4-14 22391067-12 2012 CONCLUSION: We showed that simvastatin inhibits TGF-beta-1-induced myofibroblast differentiation (expression of alpha-SMA) and collagen production in NPDFs and Rho/Rock and TGF-beta/Smad signaling is involved as an underlying mechanism. Simvastatin 27-38 transforming growth factor beta 1 Homo sapiens 48-58 22391067-12 2012 CONCLUSION: We showed that simvastatin inhibits TGF-beta-1-induced myofibroblast differentiation (expression of alpha-SMA) and collagen production in NPDFs and Rho/Rock and TGF-beta/Smad signaling is involved as an underlying mechanism. Simvastatin 27-38 transforming growth factor beta 1 Homo sapiens 48-56 21968503-13 2011 TGF-beta-inducible PAI-1 expression was attenuated by simvastatin and curcumin, a natural polyphenol. Simvastatin 54-65 transforming growth factor beta 1 Homo sapiens 0-8 19023089-4 2009 Transforming growth factor (TGF)-beta1 was also applied as a disease stimulus to VICs on 2-D surfaces or encapsulated in 3-D collagen gels and combined with different temporal applications of simvastatin. Simvastatin 192-203 transforming growth factor beta 1 Homo sapiens 0-38 21864337-0 2011 Simvastatin inhibits TGFbeta1-induced fibronectin in human airway fibroblasts. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 21-29 21864337-8 2011 RESULTS: Immunoblotting revealed concentration-dependent simvastatin inhibition of TGFbeta1 (2.5 ng/ml, 48 h)-induced fibronectin. Simvastatin 57-68 transforming growth factor beta 1 Homo sapiens 83-91 21864337-10 2011 The effects of simvastatin were mimicked by GGTI-286, but not FTI-277, suggesting fundamental involvement of GGT1 in TGFbeta1-induced signaling. Simvastatin 15-26 transforming growth factor beta 1 Homo sapiens 117-125 20463291-6 2011 Simvastatin also abrogated TGFbeta1-induced collagen I and fibronectin expression, and prevented collagen I secretion. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 27-35 20463291-9 2011 Moreover, simvastatin and GGTI-286 both prevented TGFbeta1-induced membrane association of RhoA, a downstream target of GGT1. Simvastatin 10-21 transforming growth factor beta 1 Homo sapiens 50-58 21864337-11 2011 Asthmatic fibroblasts exhibited greater TGFbeta1-induced fibronectin expression compared to non-asthmatic cells; this enhanced response was effectively reduced by simvastatin. Simvastatin 163-174 transforming growth factor beta 1 Homo sapiens 40-48 19358180-3 2009 This study assessed the effects of simvastatin on TGF-beta1-mediated intestinal fibroblast activation. Simvastatin 35-46 transforming growth factor beta 1 Homo sapiens 50-59 19358180-11 2009 Simvastatin pretreatment inhibited TGF-beta1-mediated phosphorylation of smad-3. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 35-44 19358180-12 2009 CONCLUSION: Simvastatin abrogates TGF-beta1-mediated intestinal fibroblast activation by inhibition of smad-3 phosphorylation. Simvastatin 12-23 transforming growth factor beta 1 Homo sapiens 34-43 19023089-7 2009 These effects were mimicked in 3-D cultures, wherein simvastatin reversed TGF-beta1-induced contraction. Simvastatin 53-64 transforming growth factor beta 1 Homo sapiens 74-83 15298857-5 2004 Signaling pathways driving simvastatin"s effects on CTGF/TGF-beta interaction were evaluated using transient reporter transfection of a CTGF promoter construct. Simvastatin 27-38 transforming growth factor beta 1 Homo sapiens 57-65 18203812-8 2008 Simvastatin attenuated effects of both IL-17 and TGF-beta. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 49-57 18203812-9 2008 We have demonstrated the ability of simvastatin to attenuate release of airway neutrophilic and remodeling mediators and to inhibit their upregulation by TGF-beta and IL-17. Simvastatin 36-47 transforming growth factor beta 1 Homo sapiens 154-162 16045013-6 2005 TGFbeta1 decreased in the simvastatin and benazepril group compared with the benazepril group (P < 0.01). Simvastatin 26-37 transforming growth factor beta 1 Homo sapiens 0-8 15677772-5 2005 Simvastatin significantly inhibited (P < 0.05) CTGF gene and protein expression, overriding the induction by transforming growth factor-beta1, a known potent inducer of CTGF. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 112-144 15298857-6 2004 Inhibition of CTGF promoter activity by simvastatin was most marked at 10 muM concentration, reducing activity by 76.2 and 51.8% over TGF-beta-stimulated cultures in IPF and normal fibroblasts, respectively. Simvastatin 40-51 transforming growth factor beta 1 Homo sapiens 134-142 15298857-8 2004 Indeed, the specific Rho inhibitor C3 exotoxin significantly (P < 0.05) suppressed TGF-beta-induced CTGF promoter activity in transfected lung fibroblasts, a finding further supported by transfection of dominant-negative and constitutively active RhoA constructs, thus demonstrating that simvastatin through a Rho signaling mechanism in lung fibroblasts can modulate CTGF expression and interaction with TGF-beta. Simvastatin 291-302 transforming growth factor beta 1 Homo sapiens 86-94 35599097-0 2022 Corrigendum to "Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-beta1/Gfi-1" (Canc. Simvastatin 16-27 transforming growth factor beta 1 Homo sapiens 136-145 10500210-5 1999 Simvastatin stimulated the expression of TGFbetaRII, TGFbeta(1), and PAI-1 at the level of transcription. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 41-48 10500210-6 1999 Experiments using specific inhibitors of different branches of the cholesterol metabolic pathway demonstrated that simvastatin exerted its effect on TGFbeta signaling by inhibition of the geranylgeranylation pathway. Simvastatin 115-126 transforming growth factor beta 1 Homo sapiens 149-156 30536599-9 2019 Additionally, TGF-beta1 stimulation showed a twofold increase in alpha-SMA protein expression, which was reversed to non-stimulated levels after treatment with Y-27632 and simvastatin. Simvastatin 172-183 transforming growth factor beta 1 Homo sapiens 14-23 31934265-0 2019 Simvastatin Mitigates Apoptosis and Transforming Growth Factor-Beta Upregulation in Stretch-Induced Endothelial Cells. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 36-67 31934265-12 2019 This study demonstrated that simvastatin could mitigate EC apoptosis and TGF-beta upregulation induced by continuous stretch by reducing the level of ROS. Simvastatin 29-40 transforming growth factor beta 1 Homo sapiens 73-81 30536599-14 2019 In our experiments, Rho-kinase inhibition and simvastatin treatment were shown to prevent this in TGF-beta1-stimulated cells on an RNA and protein level through the inhibition of YAP/TAZ nuclear translocation. Simvastatin 46-57 transforming growth factor beta 1 Homo sapiens 98-107 30220377-0 2018 Simvastatin reduces TGF-beta1-induced SMAD2/3-dependent human ventricular fibroblasts differentiation: Role of protein phosphatase activation. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 20-29 30220377-9 2018 Effect of simvastatin on TGF-beta1-induced fibroblast activation was annulled by okadaic acid, an inhibitor of protein-phosphatase. Simvastatin 10-21 transforming growth factor beta 1 Homo sapiens 25-34 30220377-10 2018 CONCLUSIONS: This proof-of-concept study using an in vitro experimental cell culture model identifies the protective role of simvastatin against TGF-beta1-induced hVF transformation into activated myofibroblasts through activation of protein phosphatase, a novel target that can be therapeutically modulated to curb excessive cardiac fibrosis associated with maladaptive cardiac remodeling. Simvastatin 125-136 transforming growth factor beta 1 Homo sapiens 145-154 30220377-4 2018 We aimed to assess whether simvastatin-mediated reduction in TGF-beta1-augmented profibrotic response involves reduction in phospho-SMAD2/3 owing to activation of protein-phosphatase in hVFs. Simvastatin 27-38 transforming growth factor beta 1 Homo sapiens 61-70 30220377-7 2018 Simvastatin (1 muM) reduced effect of TGF-beta1 (5 ng/mL) on hVF proliferation, myofibroblast differentiation (reduced alpha-smooth muscle actin [alpha-SMA-expression]) and activation (decreased procollagen-peptide release). Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 38-47 30220377-8 2018 Simvastatin also reduced TGF-beta1-stimulated time-dependent increases in SMAD2/3 phosphorylation and nuclear translocation, mediated through catalytic activation of protein-phosphatases PPM1A and PP2A, which physically interact with SMAD2/3, thereby promoting their dephosphorylation. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 25-34 26574150-5 2016 The effects of simvastatin on the EMT induced by LPS or TGF-beta1 were determined by the changes in the levels of EMT markers and TLR4 and in the c-Jun N-terminal kinase (JNK), p38, and nuclear factor-kappaB (NF-kappaB) signaling pathways. Simvastatin 15-26 transforming growth factor beta 1 Homo sapiens 56-65 27840243-0 2017 Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-beta1/Gfi-1 axis. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 120-129 27840243-6 2017 Simvastatin induced Gfi-1 expression, which increased the sensitivity of PDAC cells to gemcitabine by decreasing TGF-beta1 secretion by TAMs. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 113-122 27840243-8 2017 Simvastatin also reversed the effects of gemcitabine on the expression of TGF-beta1 and Gfi-1 and reduced the resistance of PDAC to gemcitabine in vivo. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 74-83 27840243-9 2017 These results provide the first evidence that simvastatin attenuates the TAM-mediated gemcitabine resistance of PDAC by blocking the TGF-beta1/Gfi-1 axis. Simvastatin 46-57 transforming growth factor beta 1 Homo sapiens 133-142 26574150-10 2016 The suppressive effects of simvastatin pretreatment on the induction of the EMT by TGF-beta1 were also demonstrated in H69 cells. Simvastatin 27-38 transforming growth factor beta 1 Homo sapiens 83-92 26574150-11 2016 CONCLUSIONS: Our results demonstrate that LPS or TGF-beta1 promote the EMT in BECs that that pretreatment with simvastatin inhibited the induced EMT by downregulating toll-like receptor 4 and NF-kappaB phosphorylation. Simvastatin 111-122 transforming growth factor beta 1 Homo sapiens 49-58 30024693-1 2016 Objective: To explore the effect of simvastatin on the proliferation, apoptosis and protein expressions of keloid fibroblasts under normoxia,hypoxia or TGF-beta1 treatment. Simvastatin 36-47 transforming growth factor beta 1 Homo sapiens 152-161 27123120-0 2016 Simvastatin blocks TGF-beta1-induced epithelial-mesenchymal transition in human prostate cancer cells. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 19-28 27123120-5 2016 It was demonstrated that simvastatin inhibited the EMT as assessed by reduced expression of N-cadherin and vimentin, and increased E-cadherin in TGF-beta1 treated DU145 PCa cells. Simvastatin 25-36 transforming growth factor beta 1 Homo sapiens 145-154 27123120-6 2016 Furthermore, simvastatin inhibited TGF-beta1-induced migration and invasion of DU145 cells. Simvastatin 13-24 transforming growth factor beta 1 Homo sapiens 35-44 27123120-9 2016 In the non-Smad pathway, simvastatin reduced TGF-beta1-induced p38 MAPK phosphorylation, but had no effect on TGF-beta1-induced Erk1/2 phosphorylation. Simvastatin 25-36 transforming growth factor beta 1 Homo sapiens 45-54 27123120-10 2016 Simvastatin attenuated TGF-beta1-induced EMT, cell migration and invasion in DU145 cells. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 23-32 30024693-5 2016 Results: It showed that simvastatin could inhibit the proliferation of KFs in a concentration-and time-dependent manner with the concentration range of 10-500 mu mol/L for 24 h and 0.1-500 mu mol/L for 48 h. This inhibitory effect could be significantly enhanced when cells were incubated under hypoxia for 48h with 10-500 mu mol/L simvastatin.10 mu mol/L simvastatin could not influence the apoptosis of KFs under normoxia or TGF-beta1 treatment, neither incubated for 24 h nor 48 h.When incubated under hypoxia,10 mu mol/L simvastatin could significantly induce the apoptosis of KFs, with the rate of 155.6% for 24 h and 478.8% for 48 h, compared with no-drug control. Simvastatin 24-35 transforming growth factor beta 1 Homo sapiens 427-436 26559850-10 2015 RESULTS: Simvastatin (5 mg/kg/day) improved clinical outcome, induced an increase in TGF-beta mRNA expression and inhibited IL-6, IL-12p40, IL-12p70, RANTES and MIP-1beta secretion (p < 0.05). Simvastatin 9-20 transforming growth factor beta 1 Homo sapiens 85-93 24098525-10 2013 Simvastatin inhibited LX-2 cells activation due to TGF-beta1 or L-NAME by increasing the expression of eNOS and decreasing the expression of iNOS. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 51-60 24506800-9 2014 Moreover, the levels of MMP-9 and TGF-beta1, factors involved in the breakdown of basement membrane and fibroproliferation, were lower in patients with PDR having simvastatin medication. Simvastatin 163-174 transforming growth factor beta 1 Homo sapiens 34-43 24471776-10 2014 Simvastatin suppressed TGF-beta1-induced type I collagen, CTGF, and alpha-SMA production in a concentration-dependent manner. Simvastatin 0-11 transforming growth factor beta 1 Homo sapiens 23-32 24471776-11 2014 The TGF-beta1-induced Smad2 and Smad3 phosphorylation levels were abrogated by simvastatin pretreatment. Simvastatin 79-90 transforming growth factor beta 1 Homo sapiens 4-13 24471776-13 2014 A RhoA activation assay showed that preincubation with simvastatin significantly blocked TGF-beta1-induced RhoA activation. Simvastatin 55-66 transforming growth factor beta 1 Homo sapiens 89-98 24471776-16 2014 In conclusion, the present study suggests that simvastatin is an effective inhibitor of TGF-beta1-induced type I collagen, CTGF, and alpha-SMA production in keloid fibroblasts. Simvastatin 47-58 transforming growth factor beta 1 Homo sapiens 88-97